Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults

@article{Dorosch2019EfficacyOA,
  title={Efficacy of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Preventative Treatment of Episodic Migraine in Adults},
  author={Tetiana Dorosch and Christine Anne Ganzer and M. Lin and Alon Seifan},
  journal={Current Pain and Headache Reports},
  year={2019},
  volume={23}
}
Systematic review of angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARB) in the prophylactic treatment of adults with migraine. To identify gaps in research and provide guidance for future clinical trials. A search was completed using PubMed, MEDLINE, Embase, and the Cochrane Library January 1, 1990 through December 31, 2017. The following are keywords used in the search: migraine, migraine prophylaxis/prevention, renin-angiotensin-aldosterone… Expand
Preventive Migraine Treatment
TLDR
Many pharmacologic and nonpharmacologic treatment options are available for the prevention of migraine, including newer therapies aimed at the CGRP pathway as well as older treatments with good evidence for efficacy. Expand
Real world effectiveness and tolerability of candesartan in the treatment of migraine: a retrospective cohort study
TLDR
C candesartan showed beneficial effects in the preventive treatment of migraine in clinical practice, including patients with chronic migraine, medication-overuse headache and resistance to prior prophylactics. Expand
Failure of preventive treatments in migraine: an observational retrospective study in a tertiary headache center
TLDR
The mild effect of preventive drugs on migraine features and even the number of patients who were lost to follow-up or dropped out because of adverse events confirm that in severe and chronic patients, the first line of prevention can only delay a more focused therapeutic approach. Expand
Migraine review for general practice
TLDR
The migraine is approached from a practical point of view with updated information and treating migraines can be done to treatment the migraine itself and to prevent its appearance. Expand
Are Migraine Patients at Increased Risk for Symptomatic Coronavirus Disease 2019 Due to Shared Comorbidities?
TLDR
This paper focuses on the co‐existence of comorbidities of COVID‐19, in comparison with migraine, based on a wide clinical dataset and available reports, and discusses mechanisms including potential strategic roles of angiotensin‐converting enzyme 2, angiotENSin‐II, and nucleotide oligomerization domain‐like receptor family, pyrin domain containing 3 inflammasome, playing remarkable parts in the pathogenesis of CO VID‐19 and migraine. Expand
Managing Migraine in the Times of COVID-19 Pandemic
TLDR
Physicians should be made aware of the new rules of the game in treating migraines during this time of the pandemic so that these patients get optimum treatment and care and don't feel left out. Expand
COVID‐19 is a Real Headache!
TLDR
It is concluded that as a common non‐respiratory symptom of COVID‐19, headache should not be overlooked, and its characteristics should be recorded with scrutiny. Expand
Perspectives for the use of therapeutic Botulinum toxin as a multifaceted candidate drug to attenuate COVID-19
TLDR
An overview on the SARS-CoV-2 mediated pathological impact on the lungs, heart and brain is provided, the therapeutic uses of BoNTs against pulmonary failure, cardiac arrest and neurological deficits are emphasized, and the rationality for the possible use of BoNNs to prevent Sars-Cov-2 infection and manage COVID-19 is emphasized. Expand
Migraine Care in the Era of COVID‐19: Clinical Pearls and Plea to Insurers
To outline strategies for the treatment of migraine which do not require in‐person visits to clinic or the emergency department, and to describe ways that health insurance companies can removeExpand
The Risks or Lack Thereof of Migraine Treatments in Vascular Disease
Patients with migraine have a co‐morbidity with vascular diseases such as hypertension, coronary heart disease, and stroke.
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
ACE and ARB Agents in the Prophylactic Therapy of Migraine—How Effective Are They?
TLDR
Based upon biologic plausibility, the quality of evidence for efficacy from clinical trials, and recommendations in published guidelines, ACE inhibitors and ARBs are considered as second- or third-line options for migraine prophylaxis. Expand
Treatment with telmisartan, a long-acting angiotensin II receptor blocker, prevents migraine attacks in Japanese non-responders to lomerizine
TLDR
The present study supported that telmisartan treatment had preventive effects in 90% of lomerizine non-responders, and significantly decreased frequency of headache days and headache severity. Expand
Renin angiotensin system: A novel target for migraine prophylaxis
TLDR
A new class of drugs like angiotensin-converting enzyme inhibitors (ACE inhibitors) and ang Elliotensin II receptor antagonists have recently been studied for their off label use in prophylaxis of migraine and a direction to use these drugs for chronic migraineurs is given. Expand
Inhibitory control of angiotensin-converting enzyme by ramipril in migraine
TLDR
Ramipril prevented migraine attacks independently from blood pressure, and this result supports a link between renin-angiotensin system and migraine pathophysiology. Expand
Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial.
TLDR
In this study, the angiotensin II receptor blocker candesartan provided effective migraine prophylaxis, with a tolerability profile comparable with that of placebo, with no significant differences in health-related quality of life. Expand
Efficacy of Enalapril in Migraine Prophylaxis: A Randomized, Double-blind, Placebo-controlled Trial
TLDR
The results support the previous suggestions on usage of ACE inhibitors in migraine prophylaxis and Enalapril according to its effect in decreasing the frequency, severity, and duration of headaches. Expand
Preventive Pharmacologic Treatments for Episodic Migraine in Adults
TLDR
Off-label angiotensin-inhibiting drugs and beta-blockers were most effective and tolerable for episodic migraine prevention and limited direct evidence as well as frequentist and exploratory network Bayesian meta-analysis showed no statistically significant differences between approved drugs. Expand
Telmisartan: A Different Angiotensin II Receptor Blocker Protecting a Different Population?
  • M. Burnier
  • Medicine
  • The Journal of international medical research
  • 2009
The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET™) showed that the angiotensin II receptor blocker (ARB) telmisartan was as protective as theExpand
A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study
TLDR
It is confirmed that candesartan 16 mg is effective for migraine prevention, with an effect size similar to propranolol 160 mg, and with somewhat different adverse events. Expand
Pathophysiological basis of migraine prophylaxis
TLDR
The pathophysiological bases for the use of antidepressants, beta-adrenergic blockers, calcium channel blockers and antiepileptic drugs in migraine prevention are presented and discussed. Expand
...
1
2
3
...